AbbVie Receives European Commission Approval Of RINVOQ For Children With Active Polyarticular Juvenile Idiopathic Arthritis Aged Two And Older
RINVOQ is now approved in the European Union for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients two years of age and older who have responded inadequately to, or who are
Share
Why It Matters
AbbVie got approval to sell RINVOQ in Europe for sick children. This means the company can now reach more patients and grow its business.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.